114 related articles for article (PubMed ID: 18224568)
1. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection.
Nielsen HJ; Brünner N; Frederiksen C; Lomholt AF; King D; Jørgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Christensen IJ; ;
Scand J Gastroenterol; 2008; 43(2):242-8. PubMed ID: 18224568
[No Abstract] [Full Text] [Related]
2. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
3. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.
Møller Sørensen N; Vejgaard Sørensen I; Ørnbjerg Würtz S; Schrohl AS; Dowell B; Davis G; Jarle Christensen I; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(7):774-86. PubMed ID: 18584515
[TBL] [Abstract][Full Text] [Related]
4. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
[TBL] [Abstract][Full Text] [Related]
5. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations.
Lomholt AF; Frederiksen CB; Christensen IJ; Brünner N; Nielsen HJ
Clin Chim Acta; 2007 May; 380(1-2):128-32. PubMed ID: 17328880
[TBL] [Abstract][Full Text] [Related]
6. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
[TBL] [Abstract][Full Text] [Related]
7. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
[TBL] [Abstract][Full Text] [Related]
8. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study.
Holten-Andersen MN; Fenger C; Nielsen HJ; Rasmussen AS; Christensen IJ; Brünner N; Kronborg O
Eur J Cancer; 2004 Sep; 40(14):2159-64. PubMed ID: 15341992
[TBL] [Abstract][Full Text] [Related]
9. [Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors].
Korotkova EA; Gershteĭn ES; Prorokov VV; Kushlinskiĭ NE
Vopr Onkol; 2009; 55(2):171-6. PubMed ID: 19514370
[TBL] [Abstract][Full Text] [Related]
10. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
[TBL] [Abstract][Full Text] [Related]
11. Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study.
Holten-Andersen L; Christensen IJ; Jensen SB; Reibel J; Laurberg S; Nauntofte B; Brünner N; Nielsen HJ
Scand J Gastroenterol; 2012 Oct; 47(10):1234-41. PubMed ID: 22871105
[TBL] [Abstract][Full Text] [Related]
12. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
13. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
[TBL] [Abstract][Full Text] [Related]
14. Plasma microRNAs: a potential biomarker for colorectal cancer?
Schetter AJ; Harris CC
Gut; 2009 Oct; 58(10):1318-9. PubMed ID: 19749133
[No Abstract] [Full Text] [Related]
15. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.
Kahlert C; Bandapalli OR; Schirmacher P; Weitz J; Brand K
Anticancer Res; 2008; 28(3A):1459-65. PubMed ID: 18630499
[TBL] [Abstract][Full Text] [Related]
16. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
[TBL] [Abstract][Full Text] [Related]
18. [Rational use of clinical detection of serum tumor markers in diagnosis of colorectal cancer].
Li Y
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2023-4. PubMed ID: 19080427
[No Abstract] [Full Text] [Related]
19. TIMP-1 as a tumor marker in breast cancer--an update.
Würtz SO; Schrohl AS; Mouridsen H; Brünner N
Acta Oncol; 2008; 47(4):580-90. PubMed ID: 18465326
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
